Abstract
Background
This study investigated patient outcomes after urinary diversion in order to manage malignant ureteral obstruction caused by non-urologic cancers and to evaluate predictive factors for overall survival.
Methods
The study retrospectively reviewed patients with non-urologic malignancies who underwent ureteral stenting or percutaneous nephrostomy for ureteral obstruction between 2006 and 2014. The variables for predicting overall survival were identified by Cox regression analysis.
Results
The study enrolled 778 patients, including 522 patients who underwent ureteral stenting and 256 patients who underwent percutaneous nephrostomy. Renal function was assessed immediately and then 2 weeks after urinary diversion. The median survival period was 5 months (interquartile range [IQR] 2–12 months). A total of 708 patients died. The patients who received chemotherapy after urinary diversion had a survival gain of 7 months compared with the patients who did not receive subsequent chemotherapy (p < 0.001). The survival rate did not differ between the various types of urinary diversion (p = 0.451). In the multivariate analysis, lower survival rates were significantly associated with male sex; previous chemotherapy without radiotherapy; an increasing number of events related to malignant dissemination; low preoperative hemoglobin (< 10 mg/dL), albumin (< 3 g/dL), and estimated glomerular filtration (< 60 mL/min/1.73 m2) rates; and no subsequent chemotherapy or radiotherapy.
Conclusions
In cases of ureteral obstruction caused by non-urologic malignancies, the overall survival was poor. However, the patients who received chemotherapy after urinary diversion had a survival gain of 7 months. Therefore, urinary diversion could be considered to preserve renal function for subsequent chemotherapy, whereas patients with the poor prognostic factors should be presented with the option of no intervention.
Similar content being viewed by others
References
Prentice J, Amer T, Tasleem A, Aboumarzouk O. Malignant ureteric obstruction decompression: how much gain for how much pain? A narrative review. J R Soc Med. 2018;111:125–35.
Kouba E, Wallen EM, Pruthi RS. Management of ureteral obstruction due to advanced malignancy: optimizing therapeutic and palliative outcomes. J Urol. 2008;180:444–50.
Shekarriz B, Shekarriz H, Upadhyay J, et al. Outcome of palliative urinary diversion in the treatment of advanced malignancies. Cancer. 1999;85:998–1003.
Chung SY, Stein RJ, Landsittel D, et al. 15-Year experience with the management of extrinsic ureteral obstruction with indwelling ureteral stents. J Urol. 2004;172:592–5.
Cordeiro MD, Coelho RF, Chade DC, et al. A prognostic model for survival after palliative urinary diversion for malignant ureteric obstruction: a prospective study of 208 patients. BJU Int. 2016;117:266–71.
Jeong IG, Han KS, Joung JY, Seo HK, Chung J. The outcome with ureteric stents for managing non-urological malignant ureteric obstruction. BJU Int. 2007;100:1288–91.
Wong LM, Cleeve LK, Milner AD, Pitman AG. Malignant ureteral obstruction: outcomes after intervention: have things changed? J Urol. 2007;178:178–83; discussion 183.
NICE Guidance–Prostate cancer: diagnosis and management: (c) NICE (2019) prostate cancer: diagnosis and management. BJU Int. 2019;124:9–26.
Sountoulides P, Pardalidis N, Sofikitis N. Endourologic management of malignant ureteral obstruction: indications, results, and quality-of-life issues. J Endourol. 2010;24:129–42.
Aravantinos E, Anagnostou T, Karatzas AD, Papakonstantinou W, Samarinas M, Melekos MD. Percutaneous nephrostomy in patients with tumors of advanced stage: treatment dilemmas and impact on clinical course and quality of life. J Endourol. 2007;21:1297–302.
Kanou T, Fujiyama C, Nishimura K, Tokuda Y, Uozumi J, Masaki Z. Management of extrinsic malignant ureteral obstruction with urinary diversion. Int J Urol. 2007;14:689–92.
Yoon JH, Park S, Park S, Moon KH, Cheon SH, Kwon T. Renal function is associated with prognosis in stent-change therapy for malignant ureteral obstruction. Investig Clin Urol. 2018;59:376–82.
Ishioka J, Kageyama Y, Inoue M, Higashi Y, Kihara K. Prognostic model for predicting survival after palliative urinary diversion for ureteral obstruction: analysis of 140 cases. J Urol. 2008;180:618–21; discussion 621.
Migita K, Watanabe A, Samma S, Ohyama T, Ishikawa H, Kagebayashi Y. Clinical outcome and management of ureteral obstruction secondary to gastric cancer. World J Surg. 2011;35:1035–41.
Izumi K, Mizokami A, Maeda Y, Koh E, Namiki M. Current outcome of patients with ureteral stents for the management of malignant ureteral obstruction. J Urol. 2011;185:556–61.
Nariculam J, Murphy DG, Jenner C, et al. Nephrostomy insertion for patients with bilateral ureteric obstruction caused by prostate cancer. Br J Radiol. 2009;82:571–6.
Jalbani MH, Deenari RA, Dholia KR, Oad AK, Arbani IA. Role of percutaneous nephrostomy (PCN) in malignant ureteral obstruction. J Pak Med Assoc. 2010;60:280–3.
Wilson JR, Urwin GH, Stower MJ. The role of percutaneous nephrostomy in malignant ureteric obstruction. Ann R Coll Surg Engl. 2005;87:21–4.
Allen DJ, Longhorn SE, Philp T, Smith RD, Choong S. Percutaneous urinary drainage and ureteric stenting in malignant disease. Clin Oncol R Coll Radiol. 2010;22:733–9.
Feng MI, Bellman GC, Shapiro CE. Management of ureteral obstruction secondary to pelvic malignancies. J Endourol. 1999;13:521–4.
Ganatra AM, Loughlin KR. The management of malignant ureteral obstruction treated with ureteral stents. J Urol. 2005;174:2125–8.
Alawneh A, Tuqan W, Innabi A, et al. Clinical factors associated with a short survival time after percutaneous nephrostomy for ureteric obstruction in cancer patients: an updated model. J Pain Symptom Manage. 2016;51:255–61.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosure
There are no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Heo, J.E., Jeon, D.Y., Lee, J. et al. Clinical Outcomes After Urinary Diversion for Malignant Ureteral Obstruction Secondary to Non-urologic Cancer: An Analysis of 778 Cases. Ann Surg Oncol 28, 2367–2373 (2021). https://doi.org/10.1245/s10434-020-09423-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-020-09423-4